Oroxylin A reverses multi-drug resistance of human hepatoma BEL7402/5-FU cells via downregulation of P-glycoprotein expression by inhibiting NF-κB signaling pathway

Mol Carcinog. 2012 Feb;51(2):185-95. doi: 10.1002/mc.20789. Epub 2011 May 6.

Abstract

In this study, oroxylin A showed strong reversal potency in BEL7402/5-FU cells and the reversal fold (RF) reached 4.69. Simultaneously, rhodamine-123 accumulation assay and flow cytometry analysis demonstrated oroxylin A could increase drug accumulation. When combined with oroxylin A, 5-FU showed inducing apoptosis effect more seriously in DAPI staining experiment. Moreover, the mRNA and protein expression of multi-drug resistance gene (MDR1) were also decreased by oroxylin A. Further experiments exhibited that oroxylin A can downregulate P-gp expression through inhibiting nuclear factor-κB (NF-κB) signaling pathway, which might be the mechanism of reversal resistance of oroxylin A. In summary, oroxylin A could be a good candidate for the development of new MDR reversal agent and its reversal mechanism probably due to the suppression of P-gp expression via inhibiting NF-κB signaling pathway.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / metabolism*
  • Blotting, Western
  • Cell Line, Tumor
  • Down-Regulation
  • Drug Resistance, Multiple*
  • Drug Resistance, Neoplasm*
  • Flavonoids / pharmacology*
  • Humans
  • Immunohistochemistry
  • NF-kappa B / metabolism*
  • Reverse Transcriptase Polymerase Chain Reaction
  • Signal Transduction*

Substances

  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Flavonoids
  • NF-kappa B
  • 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one